Short-Term Cost-Effectiveness of Switching to Insulin Degludec in Japanese Patients with Type 2 Diabetes Receiving Basal–Bolus Therapy
Crossref DOI link: https://doi.org/10.1007/s13300-019-0635-1
Published Online: 2019-06-05
Published Print: 2019-08
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Langer, Jakob
Wolden, Michael L.
Shimoda, Seiya
Sato, Miki
Araki, Eiichi
Funding for this research was provided by:
Novo Nordisk Pharma Ltd. Japan
Text and Data Mining valid from 2019-06-05
Version of Record valid from 2019-06-05
Article History
Received: 31 January 2019
First Online: 5 June 2019